Crystalline form of quinoline derivative inhibitor, preparation method therefor and use thereof

MYPI2025001053A0Undetermined Publication Date: 2024-02-29TRANSTHERA SCIENCES (NANJING) INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001053
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-30
Filing Date
2023-08-29
Publication Date
2024-02-29

AI Technical Summary

Technical Problem

Existing TAM family kinases and CSF1R kinase inhibitors have limited effectiveness in the treatment of drug-resistant diseases, especially the lack of effective drugs for drug-resistant cancer treatment caused by NTRK mutations.

Method used

The methanesulfonate crystal forms of quinoline derivatives were developed, and their crystal forms were prepared by specific preparation methods, and combined with drug carriers to form pharmaceutical preparations for selective inhibition of TAM family and CSF1R kinases for treatment and prevention by Drug-resistant diseases caused by NTRK.

Benefits of technology

The methanesulfonate crystal form of this quinoline derivative shows good physical and chemical properties and pharmacological stability, improves the efficacy and pharmacokinetic properties, can effectively inhibit related tyrosine kinases, and significantly improves the drug resistance type The therapeutic effect of cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025001053_DRAWING_001
    Figure PI2025001053_DRAWING_001
  • Figure PI2025001053_DRAWING_002
    Figure PI2025001053_DRAWING_002
  • Figure PI2025001053_DRAWING_003
    Figure PI2025001053_DRAWING_003
Patent Text Reader

Abstract

The present invention relates to the technical field of medicines, and in particular, to a mesylate crystalline form of a TAM family kinase and / or CSF1R kinase and / or NTRK inhibitor shown in a formula (I), a preparation method therefor and a pharmaceutical use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Crystal form of quinoline derivative inhibitor, preparation method and use thereof

[0001] Citation of Related Applications

[0002] The present invention claims priority to invention patent application No. 202211052009.8, filed in China on August 30, 2022, entitled “Crystal form of quinoline derivative inhibitor, preparation method and use thereof”, and the entire contents of the above patent application are incorporated herein by reference. Technical Field

[0003] The present invention belongs to the field of pharmaceutical technology and specifically relates to a crystalline form of a TAM family kinase / or CSF1R kinase inhibitor, its preparation method, and pharmaceutical use. The crystalline form of the present invention can selectively inhibit the TAM family tyrosine kinase and / or CSF1R kinase, and can be used to treat and / or prevent diseases mediated by abnormal expression of TAM family kinases and / or CSF1R kinase receptors and / or their ligands. Furthermore, the crystalline form of the present invention can also be used to treat and / or prevent related diseases caused by NTRK, more specifically, can be used to treat and / or prevent related diseases with drug resistance caused by NTRK mutations. Background Art

[0004] The TAM family includes three members: Axl, Mer, and Tyro-3. This family comprises an extracellular domain, a transmembrane domain, and a conserved intracellular kinase domain. Axl (also known as UFO, Ark, Tyro-7, and JTK1), Mer (also known as c-Mer, Mertk, Eyk, Nyk, and Tyro-12), Tyro-3 (also known as Sky, Byk, Rse, and Dtk), galectin-3, Gas6, and ProS are abnormally expressed in a variety of solid tumors, including lung cancer, gastric cancer, and liver cancer, as well as in various hematological malignancies, including AML, ALL, and CML. These expressions are strongly correlated with poor prognosis, disease progression, tumor metastasis, and drug resistance (Douglas K, Nature reviews, 2014). Axl, a tyrosine kinase, has been shown to contribute to EGFR inhibitor resistance in NSCLC and is closely associated with the metastasis of various solid tumors.

[0005] Colony Stimulating Factor 1 Receptor (CSF1R), also known as c-FMS, FMS, FIM2, MCSF, and CD115, is a single-chain transmembrane glycoprotein composed of 972 amino acid residues. It belongs to the type III receptor tyrosine kinase (RTK) family, along with FLT-3, PDGFR, and KIT. In the CSF1 / CSF1R pathway, CSF1 and CSF1R form a signaling axis that promotes the growth of macrophages in the body and regulates the normal development and homeostasis of tissues and organs. Imbalances in homeostasis can lead to a variety of diseases such as inflammation, immune system diseases, and tumors.

[0006] The NTRK genes, including NTRK1, NTRK2, and NTRK3, are responsible for the synthesis of tropomyosin-related kinase (TRK) family proteins, TRKA, TRKB, and TRKC, respectively. NTRK gene fusions can occur anywhere in the body and have been found in a variety of solid tumors in adults and children, including mammary gland secretory carcinoma (MASC), colon cancer, lung cancer, pancreatic cancer, thyroid cancer, and various sarcomas. NTRK fusions occur very rarely in common cancer types, such as colon and lung cancer, with rates below 5% for both. However, they are found at extremely high rates in some rare cancer types, such as congenital renal tumors, infantile sarcomas, salivary gland cancer, and secretory breast cancer, with frequencies exceeding 90% in some cancer types (Journal of Clinical Drugs, Vol. 15, No. 12, 2017). Therefore, the development of NTRK inhibitors holds great clinical value.

[0007] In the process of drug development, the study of crystal forms is very important. The crystal form of a compound is very different from other forms in terms of stability, solubility, etc. WO2020038460A1 discloses compounds that are inhibitors of TAM family kinases and / or CSF1R kinases and / or NTRKs, which can be used to treat and / or prevent diseases mediated by abnormal expression of TAM family kinases and / or CSF1R kinase receptors and / or their ligands, including: tumors, tumor immunity, endometriosis, vascular diseases / injuries, psoriasis, visual impairment / lesions (caused by macular degeneration, diabetes, and premature birth, etc.), kidney disease, rheumatoid arthritis, osteoporosis, and other related diseases. Furthermore, they can also be used to prepare drugs for treating and / or preventing related diseases caused by NTRKs, especially drug-resistant related diseases caused by NTRK mutations. Related diseases caused by NTRKs include, but are not limited to, non-small cell lung cancer, colorectal cancer, breast secretory carcinoma-like cancer, sarcoma, astrocytoma, glioblastoma, Spitz-like melanoma, bile duct cancer, papillary thyroid cancer, breast secretory cancer, breast cancer-unknown pathological type, etc. The present inventors have studied compound 15 in order to obtain a pharmaceutically usable crystal form.

[0008] Summary of the Invention

[0009] The object of the present invention is to provide a mesylate crystalline form of the compound of formula (I) and a preparation method thereof.

[0010] The present invention provides a mesylate crystalline form I of the compound represented by formula (I):

[0011] The crystalline form of the methanesulfonate of the compound N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridazine-3-carboxamide represented by formula (I) is Form I, characterized in that, using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles has characteristic peaks at 8.13±0.2°, 14.78±0.2°, 21.82±0.2°, 22.24±0.2°, 23.91±0.2°, 24.24±0.2°, 25.19±0.2°, and 26.94±0.2°,

[0012] In one embodiment of the present invention, the mesylate salt form I of the compound represented by formula (I) has characteristic peaks at 11.11±0.2°, 17.37±0.2°, and 20.27±0.2° in addition to the characteristic peaks described above, by X-ray powder diffraction expressed in 2θ angles using Cu-Kα radiation.

[0013] In one embodiment of the present invention, the mesylate salt form I of the compound represented by formula (I) has characteristic peaks at 12.52±0.2°, 13.75±0.2°, and 19.13±0.2° in addition to the characteristic peaks described above, by X-ray powder diffraction expressed in 2θ angles using Cu-Kα radiation.

[0014] In one embodiment of the present invention, the mesylate salt of the compound of formula (I), Form I, exhibits an X-ray powder diffraction pattern substantially as shown in FIG1 when using Cu-Kα radiation.

[0015] The present invention also provides a method for preparing the mesylate crystalline form I of the compound represented by formula (I):

[0016] The compound of formula (I) is dissolved in a single or mixed solvent and stirred until completely dissolved. Then, methanesulfonic acid is slowly added while stirring, and the crystalline form I is precipitated by stirring.

[0017] In one embodiment of the present invention, the single or mixed solvent is selected from the group consisting of: isopropanol, methanol, ethanol, tetrahydrofuran, dichloromethane, 1,4-dioxane, toluene, acetone, ethyl acetate, acetonitrile, methyl tert-butyl ether, 2-methyltetrahydrofuran, dimethyl sulfoxide, and water, or a mixture of several thereof.

[0018] In one embodiment of the present invention, the single or mixed solvent is selected from the group consisting of methanol, ethanol, tetrahydrofuran, dichloromethane, 1,4-dioxane, and an isopropanol / ethanol mixed solution.

[0019] In one embodiment of the present invention, the ratio of the isopropyl alcohol / ethanol mixed solution is selected from 1:1 to 6:1, preferably, the ratio is selected from 2:1 to 5:1, and more preferably, the ratio is selected from 2:1 to 3:1.

[0020] In one embodiment of the present invention, when the single or mixed solvent is selected from: isopropyl alcohol, 1,4-dioxane, the stirring is carried out under heating conditions, and the heating temperature is 40°C to 60°C, preferably, the temperature is 45°C to 55°C.

[0021] In one embodiment of the present invention, the stirring is carried out at room temperature or under heating conditions, and the room temperature or heating conditions are 0°C-70°C, preferably 10°C-60°C. Preferably, the room temperature is 10°C-30°C, preferably 15°C-25°C; preferably, the heating is 40°C-60°C, more preferably 45°C-55°C.

[0022] In one embodiment of the present invention, the room temperature refers to 15°C to 25°C.

[0023] In one embodiment of the present invention, the heating refers to heating to above 30°C.

[0024] In one embodiment of the present invention, the single or mixed solvent is used in an amount of 20-30 times the volume of the compound of formula (I).

[0025] In one embodiment of the present invention, the single or mixed solvent is used in an amount of 5-50 times the volume of the compound of formula (I), preferably 6-40 times the volume, further preferably 7-35 times the volume, and more preferably 8-25 times the volume.

[0026] The present invention provides a mesylate salt crystalline form II of the compound represented by formula (I):

[0027] The crystalline form of the methanesulfonate of the compound N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridazine-3-carboxamide represented by formula (I) is crystalline form II, characterized in that, using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles has characteristic peaks at 12.66±0.2°, 13.68±0.2°, 15.74±0.2°, 18.57±0.2°, 21.16±0.2°, and 22.19±0.2°.

[0028] In one embodiment of the present invention, the mesylate salt form II of the compound represented by formula (I) uses Cu-Kα radiation and X-ray powder diffraction expressed in 2θ angles. In addition to the characteristic peaks described above, there are also characteristic peaks at 18.09±0.2°, 20.13±0.2°, 24.88±0.2°, and 26.31±0.2°.

[0029] In one embodiment of the present invention, the mesylate salt form II of the compound represented by formula (I) uses Cu-Kα radiation and X-ray powder diffraction expressed in 2θ angles. In addition to the characteristic peaks described above, there are also characteristic peaks at 10.02±0.2°, 16.36±0.2°, and 29.41±0.2°.

[0030] In one embodiment of the present invention, the mesylate salt of the compound of formula (I), Form II, exhibits an X-ray powder diffraction pattern substantially as shown in FIG3 when using Cu-Kα radiation.

[0031] The present invention also provides a method for preparing the mesylate crystal form II of the compound represented by formula (I):

[0032] The compound of formula (I) was dissolved in isopropanol and stirred at room temperature until completely dissolved. Then, methanesulfonic acid was slowly added while stirring, and the crystal form II was precipitated by stirring at room temperature.

[0033] In one embodiment of the present invention, the room temperature refers to 10° C.-30° C., preferably 15° C.-25° C. The present invention provides a mesylate crystalline form III of the compound represented by formula (I):

[0034] The crystalline form of the methanesulfonate of the compound N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridazine-3-carboxamide represented by formula (I) is Form III, characterized in that, using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles has characteristic peaks at 10.32±0.2°, 10.58±0.2°, 12.55±0.2°, 17.30±0.2°, 21.49±0.2°, 21.95±0.2°, and 24.22±0.2°.

[0035] In one embodiment of the present invention, the mesylate salt form III of the compound represented by formula (I) uses Cu-Kα radiation and X-ray powder diffraction expressed in 2θ angles. In addition to the characteristic peaks described above, there are also characteristic peaks at 9.47±0.2°, 13.04±0.2°, 20.66±0.2°, and 23.61±0.2°.

[0036] In one embodiment of the present invention, the mesylate salt form III of the compound represented by formula (I) uses Cu-Kα radiation and X-ray powder diffraction expressed in 2θ angles. In addition to the characteristic peaks described above, there are also characteristic peaks at 8.61±0.2°, 15.34±0.2°, and 25.71±0.2°.

[0037] In one embodiment of the present invention, the mesylate salt of the compound of formula (I), Form III, exhibits an X-ray powder diffraction pattern substantially as shown in FIG4 when using Cu-Kα radiation.

[0038] The present invention also provides a method for preparing the crystal form III of the mesylate salt of the compound represented by formula (I): dissolving the mesylate salt of the compound represented by formula (I) in acetonitrile, beating the mixture, and precipitating the crystal form III.

[0039] The present invention also provides a method for preparing the crystal form III of the mesylate salt of the compound represented by formula (I): dissolving the crystal form I of the mesylate salt of the compound represented by formula (I) in acetonitrile, beating the mixture, and precipitating the crystal form III.

[0040] In one embodiment of the present invention, the beating is carried out at a temperature selected from 0°C to 70°C, preferably, the temperature is selected from 10°C to 60°C.

[0041] The present invention provides a mesylate salt crystalline form IV of the compound represented by formula (I):

[0042] The crystalline form of the methanesulfonate of the compound N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridazine-3-carboxamide represented by formula (I) is Form IV, characterized in that, using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles has characteristic peaks at 9.71±0.2°, 12.66±0.2°, 17.59±0.2°, 19.35±0.2°, 22.01±0.2°, 23.40±0.2°, and 24.77±0.2°,

[0043] In one embodiment of the present invention, the mesylate salt form IV of the compound represented by formula (I) has characteristic peaks at 15.11±0.2°, 22.34±0.2°, and 23.92±0.2° in addition to the characteristic peaks described above, using Cu-Kα radiation and X-ray powder diffraction expressed in 2θ angles.

[0044] In one embodiment of the present invention, the mesylate salt form IV of the compound represented by formula (I) has characteristic peaks at 10.26±0.2°, 11.78±0.2°, and 12.45±0.2° in addition to the characteristic peaks described above, using Cu-Kα radiation and X-ray powder diffraction expressed in 2θ angles.

[0045] In one embodiment of the present invention, the mesylate salt of the compound of formula (I), Form IV, exhibits an X-ray powder diffraction pattern substantially as shown in FIG5 when using Cu-Kα radiation.

[0046] The present invention also provides a method for preparing the crystal form IV of the mesylate salt of the compound represented by formula (I): dissolving the mesylate salt of the compound represented by formula (I) in dichloromethane, beating the mixture, and precipitating the crystal form IV.

[0047] The present invention also provides a method for preparing the crystal form IV of the mesylate salt of the compound represented by formula (I): dissolving the crystal form I of the mesylate salt of the compound represented by formula (I) in dichloromethane, beating the mixture, and precipitating the crystal form IV.

[0048] In one embodiment of the present invention, the beating is carried out at a temperature selected from 0°C-70°C, preferably, the temperature is selected from 10°C-60°C, further preferably, the temperature is selected from 10°C-30°C, and more preferably, the temperature is selected from 15°C-25°C.

[0049] The present invention also provides a pharmaceutical composition containing the mesylate crystalline form I, II, III or IV of the compound represented by formula (I), and one or more second therapeutically active agents.

[0050] The present invention also provides a pharmaceutical preparation containing the mesylate crystal form I, crystal form II, crystal form III or crystal form IV of the compound represented by formula (I).

[0051] In some embodiments of the invention, the pharmaceutical formulation may comprise one or more pharmaceutically acceptable carriers.

[0052] The pharmaceutical carriers of the present invention can be one or more solid or liquid fillers suitable for human use. The pharmaceutical carriers preferably have sufficient purity and sufficiently low toxicity, are compatible with the compounds provided herein, and do not significantly reduce their efficacy. For example, the pharmaceutical carriers can be fillers, binders, disintegrants, lubricants, aqueous solvents, or non-aqueous solvents.

[0053] The pharmaceutical preparations of the present invention can be prepared into any pharmaceutically acceptable dosage form. A "therapeutically effective amount" of the methanesulfonate crystalline Form I, Form II, Form III, or Form IV of the compound of formula (I) is administered to a patient or subject in need of such treatment by any suitable route of administration, such as oral, parenteral, rectal, or transpulmonary administration. For oral administration, the preparations can be prepared into tablets, capsules, pills, granules, etc. For parenteral administration, the preparations can be prepared into injection solutions, sterile powders for injection, etc.

[0054] The present invention also provides the use of the mesylate salt crystalline form I, crystalline form II, crystalline form III, or crystalline form IV of the compound represented by formula (I), or a pharmaceutical preparation or pharmaceutical composition containing crystalline form I, crystalline form II, crystalline form III, or crystalline form IV in the preparation of a drug for treating and / or preventing diseases related to abnormal signaling pathways caused by abnormal expression of TAM family kinases and / or CSF1R kinase receptors and / or their ligands.

[0055] In some embodiments of the invention, the diseases mediated by abnormal expression of the TAM family kinases / and CSF1R kinase receptors and / or their ligands include at least one of the following diseases: tumors, tumor immunity, endometriosis, vascular diseases / injuries, psoriasis, visual impairment / lesions (caused by macular degeneration, diabetes, premature birth, etc.), kidney disease, rheumatoid arthritis, osteoporosis and other related diseases.

[0056] The present invention also provides the use of the mesylate crystalline form I, form II, form III, or form IV of the compound represented by formula (I), or a pharmaceutical preparation or pharmaceutical composition containing form I, form II, form III, or form IV in the preparation of a drug for treating and / or preventing related diseases caused by NTRK.

[0057] The present invention also provides the use of a mesylate salt crystalline form I, crystalline form II, crystalline form III, or crystalline form IV of the compound represented by formula (I), or a pharmaceutical preparation or pharmaceutical composition containing crystalline form I, crystalline form II, crystalline form III, or crystalline form IV in the preparation of a drug for treating and / or preventing related diseases caused by NTRK, especially drug-resistant related diseases caused by NTRK mutations. Related diseases caused by NTRK include, but are not limited to, non-small cell lung cancer, colorectal cancer, breast secretory carcinoma-like cancer, sarcoma, astrocytoma, glioblastoma, Spitz-like melanoma, bile duct cancer, papillary thyroid cancer, breast secretory cancer, breast cancer-pathological type unknown, etc.

[0058] Detailed Description of the Invention

[0059] The "room temperature" mentioned in the present invention refers to the indoor temperature, which is usually 10°C-30°C, more usually 15°C-25°C.

[0060] The "fold volume" mentioned in the present invention refers to the volume (ml) of solvent required to dissolve 1g of a substance. For example, if 20ml of solvent is required to dissolve 1g of the compound of formula (I), it is called 20-fold volume.

[0061] The "ethanol" mentioned in the present invention includes anhydrous ethanol and a mixed solution of ethanol and water. The ethanol used in the present invention has a content of ≥95.0%.

[0062] The "methanol" mentioned in the present invention refers to methanol with a content of ≥98%, including but not limited to analytical grade, industrial grade, and anhydrous methanol.

[0063] As used herein, a "therapeutically effective amount" refers to an amount of a crystalline form of a compound, composition, or pharmaceutical formulation that, when administered to a patient, at least alleviates the symptoms of the patient's condition. The actual amount comprising a "therapeutically effective amount" will vary depending on a variety of circumstances, including, but not limited to, the specific condition being treated, the severity of the condition, the patient's physical condition and health, and the route of administration. A skilled medical practitioner can readily determine an appropriate amount using methods known in the medical field.

[0064] Excellent effects of the present invention

[0065] Through the research of the present invention, it is found that the crystal form of the present invention has very good physical and chemical properties and pharmaceutical stability, and also has greatly improved efficacy and pharmacokinetic properties, which is more conducive to drug development. BRIEF DESCRIPTION OF THE DRAWINGS

[0066] FIG1 is an X-ray powder diffraction (XRPD) pattern of Form I of the compound of formula (I).

[0067] FIG2 is a differential scanning calorimetry (DSC) spectrum of Form I of the compound of formula (I).

[0068] FIG3 is an X-ray powder diffraction (XRPD) pattern of Form II of the compound of formula (I).

[0069] FIG4 is an X-ray powder diffraction (XRPD) pattern of Form III of the compound of formula (I).

[0070] FIG5 is an X-ray powder diffraction (XRPD) pattern of Form IV of the compound of formula (I). DETAILED DESCRIPTION

[0071] The following further describes the above contents of the present invention in detail through specific embodiments, but it should not be understood that the scope of the above subject matter of the present invention is limited to the following embodiments. All technologies realized based on the above contents of the present invention belong to the scope of the present invention.

[0072] The abbreviations used herein are as follows: -Boc: tert-butyloxycarbonyl "RH": Relative Humidity "DMF": N,N-dimethylformamide "DCM": dichloromethane "DMSO": dimethyl sulfoxide "FaSSIF": starved small intestinal fluid "FeSSIF": satiety small intestinal fluid

[0073] Preparation Example 1: Synthesis of the intermediate 6-(4-fluorophenyl)-2-isopropyl-5-oxo-2,5-dihydropyridazine-4-carboxylic acid

[0074] Step 1: Synthesis of tert-butyl 2-isopropylhydrazine-1-carboxylate

[0075] Add tert-butyl carbazate (20.0 g, 0.151 mol), acetone (9.26 g, 0.16 mol), acetic acid (2 mL), magnesium sulfate (10.0 g), and sodium triacetoxyborohydride (96.64 g, 0.456 mol) to dichloromethane (100 mL). Allow to react overnight at room temperature. TLC confirms the reaction is complete. Filter the mixture, and concentrate the filtrate under reduced pressure to obtain the product (25 g, 95.6% yield).

[0076] Step 2: Synthesis of tert-butyl 2-(3-ethoxy-3-oxopropyl)-2-isopropylhydrazine-1-carboxylate

[0077] tert-Butyl 2-isopropylhydrazine-1-carboxylate (19.0 g, 0.109 mmol) and ethyl acrylate (12.01 g, 0.12 mol) were added to ethanol (60 mL) and heated at 80°C overnight. TLC monitored the reaction for completion. The mixture was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, and the crude product was purified by silica gel column chromatography (DCM:MeOH = 200:1 to 80:1) to obtain the product (24.2 g, yield: 81.0%).

[0078] Step 3: Synthesis of ethyl 3-(1-isopropylhydrazinyl)propionate

[0079] tert-Butyl 2-(3-ethoxy-3-oxopropyl)-2-isopropylhydrazine-1-carboxylate (24.1 g, 0.088 mol) was added to dichloromethane (75 mL), cooled to 0°C in an ice bath, trifluoroacetic acid (35 mL) was added, and the temperature was slowly raised to room temperature overnight. TLC showed that the reaction was complete, and the product was concentrated under reduced pressure (18.9 g crude product).

[0080] Step 4: Synthesis of ethyl 2-(4-fluorophenyl)-2-oxoacetate

[0081] p-Fluoroiodobenzene (10.0 g, 0.0451 mol) was added to 2-methyltetrahydrofuran (10 mL), cooled to 0°C in an ice bath, and isopropylmagnesium chloride (2 mol / L, 24.78 mL, 0.049 mol) was added. The mixture was stirred at 0°C for 30 minutes. The reaction solution was then added dropwise to a solution of diethyl oxalate (7.25 g, 0.0496 mol) in 2-methyltetrahydrofuran (50 mL). The mixture was slowly warmed to room temperature overnight. TLC indicated the reaction was complete. The reaction solution was added to aqueous citric acid solution, maintaining the pH at 5-6. The aqueous phase was extracted with ethyl acetate. The organic phases were washed, combined, and then washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA = 120:1-40:1) to obtain the product (8 g, yield: 90.5%).

[0082] Step 5: Synthesis of ethyl 3-(2-(2-ethoxy-1-(4-fluorophenyl)-2-oxoethylidene)-1-isopropylhydrazinyl)propanoate

[0083] Ethyl 2-(4-fluorophenyl)-2-oxoacetate (4.43 g, 22.6 mmol) and ethyl 3-(1-isopropylhydrazinyl)propionate (11.81 g crude product) were added to ethanol (10 mL) and heated at 80°C overnight. TLC indicated the reaction was complete. The mixture was filtered, and the filtrate was added with water and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA = 60:1 to 10:1) to obtain the product (2.3 g, yield: 28.9%).

[0084] Step 6: Synthesis of ethyl 6-(4-fluorophenyl)-2-isopropyl-5-oxo-2,3,4,5-tetrahydropyridazine-4-carboxylate

[0085] Ethyl 3-(2-(2-ethoxy-1-(4-fluorophenyl)-2-oxoethylidene)-1-isopropylhydrazinyl)propanoate (2.27 g, 6.45 mmol) was added to 2-methyltetrahydrofuran (10 mL), cooled to 0°C in an ice bath, and potassium tert-butoxide (1.81 g, 16.11 mmol) was added. The mixture was slowly warmed to room temperature overnight. TLC indicated the reaction was complete. The reaction solution was added to aqueous citric acid solution, maintaining the pH at 5-6. Extraction was performed with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the product (1.27 g, yield: 64.5%).

[0086] Step 7: Synthesis of ethyl 6-(4-fluorophenyl)-2-isopropyl-5-oxo-2,5-dihydropyridazine-4-carboxylate

[0087] Ethyl 6-(4-fluorophenyl)-2-isopropyl-5-oxo-2,3,4,5-tetrahydropyridazine-4-carboxylate (1.2 g, 3.92 mmol) and cupric chloride dihydrate (2.67 g, 15.68 mmol) were added to acetonitrile (10 mL) and reacted at 80°C for 4 hours. TLC indicated the reaction was complete. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic phases were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA = 100:1 to 40:1) to obtain the product (730.0 mg, yield: 61.2%).

[0088] Step 8: Synthesis of 6-(4-fluorophenyl)-2-isopropyl-5-oxo-2,5-dihydropyridazine-4-carboxylic acid

[0089] Ethyl 6-(4-fluorophenyl)-2-isopropyl-5-oxo-2,5-dihydropyridazine-4-carboxylate (700.0 mg, 2.3 mmol) was added to a mixture of methanol (6 mL) and water (5 mL), followed by the addition of lithium hydroxide monohydrate (284.4 mg, 6.91 mmol). The mixture was stirred at room temperature for 1 hour. TLC indicated the reaction was complete. The pH was adjusted to 2-3 with citric acid. Solids precipitated and were filtered. The filter cake was dissolved in dichloromethane, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to yield the product (600.0 mg, 94.5% yield).

[0090] Example 1 Preparation of Formula (I) Compound N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridazine-3-carboxamide

[0091] Step 1: Synthesis of 6,7-dimethoxy-4-((6-nitropyridin-3-yl)oxy)quinoline

[0092] 6,7-Dimethoxyquinolin-4-ol (15.00 g, 73.10 mmol, 1.0 eq), 5-chloro-2-nitropyridine (11.60 g, 73.10 mmol, 1.0 eq), and K2CO3 (20.20 g, 146.11 mmol, 2.0 eq) were added to DMF (120 mL) and stirred at 80°C under nitrogen overnight. The reaction was monitored for completion by TLC. The mixture was filtered, the filter cake was rinsed with dichloromethane, and the filtrate was concentrated under reduced pressure. Dissolved in dichloromethane (50 mL), the mixture was washed sequentially with distilled water (20 × 4 mL) and saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA = 1:9 to EA) to obtain the product (4.70 g, yield: 19.6%).

[0093] Step 2: Synthesis of 5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-amine

[0094] 6,7-Dimethoxy-4-((6-nitropyridin-3-yl)oxy)quinoline (4.70 g, 14.36 mmol, 1.0 eq), reduced iron powder (4.81 g, 86.16 mmol, 6.0 eq), and NH4Cl (9.22 g, 172.32 mmol, 12.0 eq) were added to a mixture of ethanol (100 mL) and water (40 mL) and stirred at 80°C for 4 h. The reaction was monitored for completion by TLC. The mixture was filtered while hot, the filter cake was rinsed with dichloromethane, and the filtrate was concentrated under reduced pressure. The aqueous phase was extracted with dichloromethane (20 mL x 3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the product (4.07 g, yield: 95.3%).

[0095] Step 3: Synthesis of N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridazine-3-carboxamide

[0096] 1-Isopropyl-4-oxo-5-(4-fluorophenyl)-1,4-dihydropyridazine-3-carboxylic acid (149.0 mg, 0.54 mmol, 1.0 eq) and 5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-amine (192.4 mg, 0.65 mmol, 1.2 eq) were dissolved in anhydrous pyridine (2 mL) and stirred for 10 min. POCl3 was slowly added dropwise until the solid dissolved. The reaction was monitored for completion by TLC. The mixture was concentrated under reduced pressure and dissolved in ethyl acetate (10 mL). The mixture was washed sequentially with 1 mol / L hydrochloric acid (5 mL), saturated aqueous sodium bicarbonate solution (5 mL), water (5 mL × 2), and saturated brine (5 mL). The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA = 1:1) to obtain the product (151 mg, yield: 50.4%).

[0097] 1 H NMR(400MHz, DMSO-d6)δ(ppm):13.08(s,1H),8.94(s,1H),8.52-8.50(d,1H),8.44-8.42(t,2H),7.98-7.95(m,2H),7.91-7.88( q,1H),7.55(s,1H),7.42(s,1H),7.37-7.33(t,2H),6.60-6.58(d,1H),4.80-4.74(m,1H),3.96-3.95(d,6H),1.54-1.53(d,6H).

[0098] Molecular formula: C 30 H 26FN5O5 molecular weight: 555.57 LC-MS (Pos, m / z) = 556.33 [M+H] + .

[0099] Example 2 Preparation of Methanesulfonate Crystal Form I of Compound of Formula (I)

[0100] 0.56 g of the compound of formula (I) was weighed into a reaction flask, 5 ml of anhydrous methanol was added, and the mixture was stirred at room temperature for 0.5 h. Then, 78 μl of methanesulfonic acid was slowly added while stirring. The mixture was stirred at room temperature for 20 h to allow crystallization. The mixture was filtered and the filter cake was dried in vacuo at 50°C to obtain the mesylate salt Form I.

[0101] Using Cu-Kα radiation, X-ray powder diffraction patterns of Form I, expressed in 2θ degrees (°), showed characteristic peaks at 8.13±0.2°, 14.78±0.2°, 21.82±0.2°, 22.24±0.2°, 23.91±0.2°, 24.24±0.2°, 25.19±0.2°, and 26.94±0.2°; further peaks at 11.11±0.2°, 17.37±0.2°, and 20.27±0.2°; and further peaks at 12.52±0.2°, 13.75±0.2°, and 19.13±0.2°. The XRPD analysis is shown in Figure 1.

[0102] The melting temperature of Form I was measured by differential scanning calorimetry and was found to be approximately 261°C-263°C, as shown in Figure 2 .

[0103] Example 3 Preparation of Methanesulfonate Crystal Form I of the Compound of Formula (I)

[0104] 0.56 g of the compound of formula (I) was weighed into a reaction flask, 5 ml of anhydrous ethanol was added, and the mixture was stirred at room temperature for 0.5 h. Then, 78 μl of methanesulfonic acid was slowly added while stirring. The mixture was stirred at room temperature for 20 h to allow crystallization. The mixture was filtered and the filter cake was dried in vacuo at 50°C to obtain the mesylate salt Form I.

[0105] When Cu-Kα radiation is used, an X-ray powder diffraction pattern substantially as shown in FIG. 1 is exhibited.

[0106] Example 4 Preparation of Methanesulfonate Crystal Form I of Compound of Formula (I)

[0107] 0.56 g of the compound of formula (I) was weighed into a reaction flask, 5 ml of tetrahydrofuran was added, and the mixture was stirred at room temperature for 10 min. Then, 78 μl of methanesulfonic acid was slowly added while stirring. The mixture was stirred at room temperature for 20 h to allow crystallization. The mixture was filtered and the filter cake was dried in vacuo at 50°C to obtain the mesylate salt Form I.

[0108] When Cu-Kα radiation is used, an X-ray powder diffraction pattern substantially as shown in FIG. 1 is exhibited.

[0109] Example 5 Preparation of Methanesulfonate Crystal Form I of the Compound of Formula (I)

[0110] 0.56 g of the compound of formula (I) was weighed into a reaction flask, 5 ml of dichloromethane was added, and the mixture was stirred at room temperature for 10 min. Then, 78 μl of methanesulfonic acid was slowly added while stirring. The mixture was stirred at room temperature for crystallization for 20 h, filtered, and the filter cake was dried in vacuo at 50°C to obtain the mesylate salt Form I.

[0111] When Cu-Kα radiation is used, an X-ray powder diffraction pattern substantially as shown in FIG. 1 is exhibited.

[0112] Example 6 Preparation of Methanesulfonate Crystal Form I of the Compound of Formula (I)

[0113] 0.56 g of the compound of formula (I) was weighed into a reaction flask, 7 ml of an isopropanol / ethanol mixed solution (isopropanol:ethanol = 5:2) was added, and the mixture was stirred at room temperature for 20 min. Then, 78 μl of methanesulfonic acid was slowly added while stirring. The mixture was stirred at room temperature for 20 h to allow crystallization. The mixture was filtered and the filter cake was dried in vacuo at 50°C to obtain the mesylate salt Form I.

[0114] When Cu-Kα radiation is used, an X-ray powder diffraction pattern substantially as shown in FIG. 1 is exhibited.

[0115] Example 7 Preparation of Methanesulfonate Crystal Form I of Compound of Formula (I)

[0116] 0.56 g of the compound of formula (I) was weighed into a reaction flask, 6 ml of isopropanol was added, and the mixture was stirred at 50°C for 0.5 h. Then, 78 μl of methanesulfonic acid was slowly added while stirring. After stirring at 50°C for 2 h, the heat was turned off and the temperature was naturally cooled to room temperature while stirring. After continuing stirring for 16 h, the mixture was filtered and the filter cake was dried in vacuo at 50°C to obtain the mesylate salt Form I.

[0117] When Cu-Kα radiation is used, an X-ray powder diffraction pattern substantially as shown in FIG. 1 is exhibited.

[0118] Example 8 Preparation of Methanesulfonate Crystal Form I of the Compound of Formula (I)

[0119] 0.56 g of the compound of formula (I) was weighed into a reaction flask, 10 ml of 1,4-dioxane was added, and the mixture was stirred at 50°C for 0.5 h. Then, 78 μl of methanesulfonic acid was slowly added while stirring. After stirring at 50°C for 2 h, the heat was turned off and the temperature was allowed to cool naturally to room temperature while stirring. Stirring was continued for 16 h, followed by filtration. The filter cake was dried in vacuo at 50°C to obtain the mesylate salt Form I. When irradiated with Cu-Kα, an X-ray powder diffraction pattern substantially as shown in Figure 1 was obtained.

[0120] Example 9 Preparation of Methanesulfonate Crystalline Form II of Compound of Formula (I)

[0121] 1.12 g of the compound of formula (I) was weighed into a reaction flask, 5 ml of isopropanol was added, and the mixture was stirred at room temperature for 0.5 h. Then, 156 μl of methanesulfonic acid was slowly added while stirring. The mixture was stirred at room temperature for 20 h to allow crystallization. The mixture was filtered and the filter cake was dried in vacuo at 50°C to obtain the mesylate salt Form II.

[0122] Using Cu-Kα radiation, X-ray powder diffraction of Form II, expressed in 2θ degrees (°), exhibited characteristic peaks at 12.66±0.2°, 13.68±0.2°, 15.74±0.2°, 18.57±0.2°, 21.16±0.2°, and 22.19±0.2°; further peaks at 18.09±0.2°, 20.13±0.2°, 24.88±0.2°, and 26.31±0.2°; and further peaks at 10.02±0.2°, 16.36±0.2°, and 29.41±0.2°. The XRPD analysis is shown in Figure 3.

[0123] Example 10 Preparation of Methanesulfonate Crystalline Form III of the Compound of Formula (I)

[0124] 1 g of mesylate salt Form I was weighed into a reaction flask, 10 ml of acetonitrile was added, and the mixture was slurried at room temperature or 50°C for 24 h, filtered, and the filter cake was vacuum dried at 50°C to obtain mesylate salt Form III.

[0125] Using Cu-Kα radiation, X-ray powder diffraction of Form III, expressed in 2θ degrees (°), exhibited characteristic peaks at 10.32 ± 0.2°, 10.58 ± 0.2°, 12.55 ± 0.2°, 17.30 ± 0.2°, 21.49 ± 0.2°, 21.95 ± 0.2°, and 24.22 ± 0.2°; further peaks at 9.47 ± 0.2°, 13.04 ± 0.2°, 20.66 ± 0.2°, and 23.61 ± 0.2°; and further peaks at 8.61 ± 0.2°, 15.34 ± 0.2°, and 25.71 ± 0.2°. The XRPD analysis is shown in Figure 4.

[0126] Example 11 Preparation of Form IV of the Methanesulfonate Salt of the Compound of Formula (I)

[0127] 1 g of mesylate salt Form I was weighed into a reaction flask, 30 ml of dichloromethane was added, and the mixture was slurried at room temperature for 24 h. The mixture was filtered, and the filter cake was dried under vacuum at 50° C. to obtain mesylate salt Form IV.

[0128] Using Cu-Kα radiation, X-ray powder diffraction of Form IV, expressed in 2θ degrees (°), exhibited characteristic peaks at 9.71±0.2°, 12.66±0.2°, 17.59±0.2°, 19.35±0.2°, 22.01±0.2°, 23.40±0.2°, and 24.77±0.2°; further peaks at 15.11±0.2°, 22.34±0.2°, and 23.92±0.2°; and further peaks at 10.26±0.2°, 11.78±0.2°, and 12.45±0.2°. The XRPD analysis is shown in Figure 5.

[0129] The present invention can be better understood according to the following experimental examples. However, it is easy for those skilled in the art to understand that the contents described in the experimental examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.

[0130] Experimental Example 1: Cell AXL Inhibitory Activity Test of the Crystalline Form of the Present Invention

[0131] H1299 is a non-small cell lung cancer cell line.

[0132] Test substance: the crystalline form of the methanesulfonate of the compound of formula (I) of the present invention, the structure of which is shown above.

[0133] Testing instruments: protein electrophoresis instrument (Bio Rad), membrane transfer instrument (Bio Rad), exposure instrument (Tanon), CO2 cell incubator (Thermo), etc.

[0134] Test method:

[0135] H1299 cells were seeded in 6-well plates (containing 10% FBS 1640 medium, 5×10 cells per well). 5 Cells were cultured at 37°C, 5% CO2 for 18 hours, then starved overnight. Compounds were added at various concentrations, with final concentrations of 0.37, 1.1, 3.3, 10, and 30 nM, and the final DMSO content was 1‰. Negative controls contained culture medium containing 1‰ DMSO. After incubation at 37°C, 5% CO2 for 60 minutes, hGAS6 (R&D, final concentration 200 ng / mL) was added to each well. After an additional 60 minutes of incubation, total cell protein was extracted and Western blotting was performed to determine the inhibitory activity of the compounds against pAXL.

[0136] The test results are shown in Table 1:

[0137] Table 1 Inhibitory activity of the crystal form of the present invention on cell pAXL

[0138] As shown in the experimental results in Table 1, the mesylate salt of the compound of formula (I) of the present invention has a significant inhibitory effect on pAXL in H1299 cells, indicating that the mesylate salt of the compound of formula (I) of the present invention can effectively inhibit AXL activity at the cellular level and is a good AXL inhibitor.

[0139] Experimental Example 2 PK evaluation of the crystal form of the present invention in rats

[0140] Animal medication and sample collection:

[0141] Experimentally, suspension solutions of Form I and Form II of the mesylate salt of the compound of formula (I) were prepared using 0.5% HPMC. The solution of the compound was orally administered to SD rats at a dose of 60 mg / kg, and blood was collected at the following time points: 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, 48 h, 72 h, and 96 h.

[0142] Animals were immobilized and their tails were heated in a water bath 10 minutes before each time point. Approximately 100 μL of blood was collected via the tail vein and placed into tubes containing EDTA-K2 anticoagulant. Blood samples were centrifuged at 8000 rpm for 6 minutes at 4°C to obtain plasma samples, which were prepared within 30 minutes of blood collection. Plasma was stored at -80°C until testing.

[0143] Sample analysis method:

[0144] The sample to be tested was removed from the -80°C freezer, thawed naturally at room temperature, and vortexed for 5 minutes. 20 μL of plasma sample was accurately pipetted into a 1.5 mL centrifuge tube; 200 μL of 100 ng / mL internal standard working solution (methanol solution of tolbutamide) was added and mixed; after vortexing for 5 minutes, centrifuged at 12,000 rpm for 5 minutes; 50 μL of supernatant was accurately pipetted into a 96-well plate pre-added with 150 μL / well of water; vortexed for 5 minutes, and then analyzed by LC-MS / MS.

[0145] Data processing method:

[0146] The test substance concentrations were output using Analyst 1.6.3 from AB. Parameters such as mean, standard deviation, and coefficient of variation were calculated using Microsoft Excel (no calculation was required for values ​​directly output from Analyst 1.6.3). PK parameters were calculated using Pharsight Phoenix 6.1 software (NCA). max is the median).

[0147] The results are shown in Table 2 below:

[0148] Table 2 PK parameters of different crystalline forms in SD rats (PO: 60 mg / kg, n=3) Note: z1 / 2 : terminal elimination half-life, T max : Time to peak blood concentration, AUC last : Area under the drug-time curve 0~96h.

[0149] The experimental results in Table 2 show that the methanesulfonate crystalline form of the compound of formula (I) of the present invention has good pharmacokinetic properties and good drugability.

[0150] Experimental Example 3 Stability Test of the Crystal Form of the Present Invention

[0151] Test substances: mesylate crystalline form I, crystalline form II, crystalline form III, and crystalline form IV of the compound of formula (I) of the present invention.

[0152] Methods: Appropriate amounts of mesylate crystalline Form I, Form II, Form III, and Form IV samples of the compound of formula (I) were taken and placed in an open container under high temperature (60°C), high humidity (RH92.5%), and light (4500±500 Lux). Samples were taken on the 5th, 10th, and 30th days to investigate changes in the properties, purity, and crystal form of the samples.

[0153] result:

[0154] Table 3 Test results of influencing factors

[0155] Conclusion: The properties and purity of the mesylate salt form I, form II, form III, and form IV of the compound of formula (I) of the present invention did not change significantly after being placed under various influencing factors for 30 days, and the sample stability was good.

[0156] Experimental Example 4 Determination of the solubility of the crystal form of the present invention in test solutions of different pH values

[0157] Test material: mesylate salt of compound of formula (I) in form I, II, III, or IV

[0158] Preparation of different pH buffer solutions:

[0159] (1) FaSSIF (pH 6.5):

[0160] ① Take 0.42g NaOH, 3.44g anhydrous NaH2PO4, and 6.19g NaCl and dissolve them in about 0.9L pure water;

[0161] ② Adjust the pH to 6.5 with 1N NaOH or 1N HCl, and add purified water to the buffer volume to 1 L at room temperature;

[0162] ③ Add 2.24 g FaSSIF powder to approximately 0.5 L of buffer and stir until the powder is completely dissolved. Make up the volume (1 L) with buffer at room temperature and let it stand for 2 hours before use.

[0163] (2) FeSSIF (pH 5.0):

[0164] ① Take 4.04g NaOH, 8.65g glacial acetic acid, and 11.87g NaCl and dissolve them in about 0.9L pure water;

[0165] ② Adjust the pH to 5.0 with 1N NaOH or 1N HCl, and add purified water to the buffer volume to 1 L at room temperature;

[0166] ③ Add 11.2 g of FaSSIF powder to approximately 0.5 L of buffer and stir until the powder is completely dissolved. Make up the volume (1 L) with buffer at room temperature and let it stand for 2 hours before use.

[0167] Experimental process:

[0168] Take an appropriate amount of the test substance and place it in a 10ml PE tube. Add 10ml of FaSSIF (pH 6.5) buffer and 10ml of FeSSIF (pH 5.0) buffer respectively. Place in a constant temperature water bath shaker at 37°C for 24 hours. After 24 hours, take a sample, centrifuge it, and dilute the supernatant to measure its solubility.

[0169] The experimental results are as follows:

[0170] Table 4 Solubility of different crystal forms in test solutions with different pH values

[0171] Conclusion: Compared with the compound of formula (I), the solubility of its mesylate salt forms I, II, III and IV in pH 5.0 and pH 6.5 test solutions is significantly improved.

[0172] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A crystalline form of the methanesulfonate salt of the compound N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridazine-3-carboxamide represented by formula (I), which is Form I, characterized in that: Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles showed characteristic peaks at 8.13±0.2°, 14.78±0.2°, 21.82±0.2°, 22.24±0.2°, 23.91±0.2°, 24.24±0.2°, 25.19±0.2°, and 26.94±0.2°.

2. The crystalline form I according to claim 1, wherein Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles also shows characteristic peaks at 11.11±0.2°, 17.37±0.2°, and 20.27±0.2°.

3. The crystalline form I according to claim 2, wherein Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles also shows characteristic peaks at 12.52±0.2°, 13.75±0.2°, and 19.13±0.2°.

4. The preparation method of the crystal form I according to claim 1, Dissolve the compound of formula (I) in a single or mixed solvent and stir until completely dissolved, then slowly add methanesulfonic acid while stirring, and stir to precipitate Form I; The single or mixed solvent is selected from the group consisting of isopropanol, methanol, ethanol, tetrahydrofuran, dichloromethane, 1,4-dioxane, toluene, acetone, ethyl acetate, acetonitrile, methyl tert-butyl ether, 2-methyltetrahydrofuran, dimethyl sulfoxide, and water, or a mixture thereof; preferably, the single or mixed solvent is selected from the group consisting of methanol, ethanol, tetrahydrofuran, dichloromethane, 1,4-dioxane, and an isopropanol / ethanol mixed solution.

5. The crystalline form of the methanesulfonate of the compound N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridazine-3-carboxamide represented by formula (I) is Form II, characterized in that: Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles showed characteristic peaks at 12.66±0.2°, 13.68±0.2°, 15.74±0.2°, 18.57±0.2°, 21.16±0.2°, and 22.19±0.2°.

6. The crystalline form II according to claim 5, characterized in that Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles also shows characteristic peaks at 18.09±0.2°, 20.13±0.2°, 24.88±0.2°, and 26.31±0.2°.

7. The crystalline form II according to claim 6, characterized in that X-ray powder diffraction using Cu-Kα and expressed in 2θ angles also showed characteristic peaks at 10.02±0.2°, 16.36±0.2°, and 29.41±0.2°.

8. A crystalline form of the methanesulfonate salt of the compound N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridazine-3-carboxamide represented by formula (I), which is Form III, characterized in that: Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles showed characteristic peaks at 10.32±0.2°, 10.58±0.2°, 12.55±0.2°, 17.30±0.2°, 21.49±0.2°, 21.95±0.2°, and 24.22±0.2°.

9. The crystalline form III according to claim 8, characterized in that Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles also shows characteristic peaks at 9.47±0.2°, 13.04±0.2°, 20.66±0.2°, and 23.61±0.2°.

10. The crystalline form III according to claim 9, characterized in that Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles also shows characteristic peaks at 8.61±0.2°, 15.34±0.2°, and 25.71±0.2°.

11. A crystalline form of the methanesulfonate salt of the compound represented by formula (I), N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridazine-3-carboxamide, which is Form IV, characterized in that: Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles showed characteristic peaks at 9.71±0.2°, 12.66±0.2°, 17.59±0.2°, 19.35±0.2°, 22.01±0.2°, 23.40±0.2°, and 24.77±0.2°.

12. The crystalline form IV according to claim 11, characterized in that Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles also shows characteristic peaks at 15.11±0.2°, 22.34±0.2°, and 23.92±0.2°.

13. The crystalline form IV according to claim 12, characterized in that Using Cu-Kα radiation, X-ray powder diffraction expressed in 2θ angles also shows characteristic peaks at 10.26±0.2°, 11.78±0.2°, and 12.45±0.2°.

14. A pharmaceutical composition comprising the crystalline form I according to any one of claims 1 to 3, the crystalline form II according to any one of claims 5 to 7, the crystalline form III according to any one of claims 8 to 10, or the crystalline form IV according to any one of claims 11 to 13, and one or more second therapeutically active agents.

15. A pharmaceutical preparation comprising the crystalline form I according to any one of claims 1 to 3, the crystalline form II according to any one of claims 5 to 7, the crystalline form III according to any one of claims 8 to 10, or the crystalline form IV according to any one of claims 11 to 13, and one or more pharmaceutically acceptable carriers.

16. Use of the crystalline form I according to any one of claims 1 to 3, the crystalline form II according to any one of claims 5 to 7, the crystalline form III according to any one of claims 8 to 10, the crystalline form IV according to any one of claims 11 to 13, the pharmaceutical composition according to claim 14, or the pharmaceutical preparation according to claim 15 in the preparation of a medicament for treating and / or preventing diseases caused by abnormal signaling pathways resulting from abnormal expression of TAM family kinases and / or CSF1R kinase receptors and / or their ligands.

17. Use of the crystalline form I according to any one of claims 1-3, the crystalline form II according to any one of claims 5-7, the crystalline form III according to any one of claims 8-10, the crystalline form IV according to any one of claims 11-13, the pharmaceutical composition according to claim 14, or the pharmaceutical preparation according to claim 15 in the preparation of a medicament for treating and / or preventing related diseases caused by NTRK.